Eppendorf's reagent business includes the Eppendorf "5-Prime" nucleic acid sample-preparation and PCR reagent product lines and related intellectual property, according to Qiagen.
The assets also comprise a "promising" pipeline of technologies for nucleic acid handling, separation, purification, and amplification.
Financial terms of the acquisition were not disclosed. However, Qiagen said it expects the reagent business to add $6 million in net sales in 2006 and $11 million in 2007. Qiagen generated $380 million in revenues in 2004, the most current annual period for which figures are available. As part of the deal, Qiagen said it also expects to incur $3 million in one-time in the fourth quarter 2005.
The alliance between the companies is intended to marry certain of the firms' technologies. For example, Eppendorf is known for its liquid-handling instruments, including pipettes, centrifuges, PCR cyclers, and work stations. Qiagen, meantime, is known for its preanalytical sample-prep tools, among other instruments and consumables. Their alliance aims to improve biological sample-management and analysis.